References
- Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblas-toma. Neuro Oncol. 2008; 10: 79–87.
- Lacroix M, Abi-Said D, Foumey DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95: 190–8.
- Stark AM, Nabavi A, Mehdom HM, Blömer U. Glioblastoma multiforme — report of 267 cases treated at a single institution. Surg Neurol. 2005; 63: 162–9.
- Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press; 2000.
- Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology. 1999; 1: 44–51.
- Scherer HJ. Cerebral astrocytomas and their derivatives. Am J Cancer. 1940; 40: 159–98.
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987–96.
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997–1003.
- Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007; 13: 2038-45.
- Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem. 2005; 74: 681–710.
- Hsieh P. Molecular mechanisms of DNA mismatch repair. Mutat Res. 2001; 486: 71–87.
- Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999; 9: 89–96.
- Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bc1-2 genes. Brain Pathol. 1998; 8: 655–67.
- Stark AM, Witzel P, Strege RJ, Hugo HH, Mehdom HM. p53, mdm2, EGFR and msh2 expression in paired initial and recurrent glioblastoma multiforme. J Neurol Neurosurg Psychiatry. 2003; 74: 779–83.
- Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, et al. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer. 2002; 1: 690–9.
- Papadopoulos N, Lindblom A. Molecular basis of HNPCC: mutations of MMR genes. Hum Mutat. 1997; 10: 89–99.
- Martinez R, Schackert HK, Plaschke J, Baretton G, Appelt H, Schackert G. Molecular mechanisms associated with chromo-somal and microsatellite instability in sporadic glioblastoma multiforme. Oncology. 2004; 66: 395–403.
- Ide T, Kitajima Y, Ohtaka K, Mitsuno M, Nakafusa Y, Miyazaki K. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. Oncol Rep. 2008; 19: 1571–6.
- Zhang H, Zhang S, Cui J, Zhang A, Shen L, Yu H. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust N Z J Obstet Gynaecol. 2008; 48: 505–9.
- Rellecke P, Kuchelmeister K, Schachenmayr W, Schlegel J. Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas. J Neurosurg. 2004; 101: 653–8.
- Maxwell JA, Johnson SP, McLendon RE, Lister DW, Home KS, Rasheed A, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res. 2008; 14: 4859–68.